Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Total Liabilities (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Total Liabilities for 6 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities fell 17.83% to $2.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.3 million, a 17.83% decrease, with the full-year FY2024 number at $2.2 million, down 34.0% from a year prior.
  • Total Liabilities was $2.3 million for Q3 2025 at Ensysce Biosciences, down from $2.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $24.6 million in Q4 2021 to a low of $1.3 million in Q2 2024.
  • A 5-year average of $6.4 million and a median of $3.4 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: skyrocketed 250.56% in 2021, then crashed 85.99% in 2023.
  • Ensysce Biosciences' Total Liabilities stood at $24.6 million in 2021, then tumbled by 59.66% to $9.9 million in 2022, then crashed by 66.12% to $3.4 million in 2023, then tumbled by 34.0% to $2.2 million in 2024, then grew by 3.94% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Total Liabilities are $2.3 million (Q3 2025), $2.5 million (Q2 2025), and $1.9 million (Q1 2025).